Product Pathways - MAPK Signaling
SignalSilence® MEK1 siRNA I #6426
|Transfection||H (M) (R)|
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Fluorescein Conjugate) #6201 (-) or SignalSilence® MEK1 siRNA I or SignalSilence® MEK1 siRNA II #6530 (+), using MEK1 (61B12) Mouse mAb #2352 and α-Tubulin (11H10) Rabbit mAb #2125. The MEK1 (61B12) Mouse mAb confirms silencing of MEK1 expression and α-Tubulin (11H10) Rabbit mAb is used to control for loading and specificity of MEK1 siRNA.
SignalSilence® MEK1 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit MEK1 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Directions for Use
CST recommends transfection with 100nM MEK1 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
MEK1 and MEK2, also called MAPK or Erk kinases, are dual-specificity protein kinases that function in a mitogen activated protein kinase cascade controlling cell growth and differentiation (1-3). Activation of MEK1 and MEK2 occurs through phosphorylation of two serine residues at positions 217 and 221, located in the activation loop of subdomain VIII, by Raf-like molecules. MEK1/2 is activated by a wide variety of growth factors and cytokines and also by membrane depolarization and calcium influx (1-4). Constitutively active forms of MEK1/2 are sufficient for the transformation of NIH/3T3 cells or the differentiation of PC-12 cells (4). MEK activates p44 and p42 MAP kinase by phosphorylating both threonine and tyrosine residues at sites located within the activation loop of kinase subdomain VIII.
Small interfering RNA (siRNA) has been used to specifically silence MEK1 expression in HEK293T cells (5).
- Crews, C.M. et al. (1992) Science 258, 478-480.
- Alessi, D.R. et al. (1994) EMBO J. 13, 1610-1619.
- Rosen, L.B. et al. (1994) Neuron 12, 1207-1221.
- Cowley, S. et al. (1994) Cell 77, 841-852.
- Castro-Obregón, S. et al. (2004) J Biol Chem 279, 17543-53.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 6568 SignalSilence® Control siRNA (Unconjugated)
- 6201 SignalSilence® Control siRNA (Fluorescein Conjugate)
- 6530 SignalSilence® MEK1 siRNA II
- 6431 SignalSilence® MEK2 siRNA I
- 9125 MEK2 Antibody
- 9146 MEK1 (30C8) Rabbit mAb
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
For Research Use Only. Not For Use In Diagnostic Procedures.